T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF

Aurelija Abraityte, Pal Aukrust, Lei Kou, Inder S. Anand, James Young, John J. V. Mcmurray, Dirk J. van Veldhuisen, Lars Gullestad, Thor Ueland*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

6 Citations (Scopus)

Abstract

BackgroundActivated leukocytes may contribute to the development and progression of heart failure (HF). We investigated the predictive value of circulating levels of stable and readily detectable markers reflecting both monocyte/macrophage and T-cell activity, on clinical outcomes in HF patients with reduced ejection fraction (HFrEF).MethodsThe association between baseline plasma levels of soluble CD163 (sCD163), macrophage migration inhibitory factor (MIF), granulysin, soluble interleukin-2 receptor (sIL-2R), and activated leukocyte cell adhesion molecule (ALCAM) and the primary endpoint of death from any cause or first hospitalization for worsening of HF was evaluated using multivariable Cox proportional hazard models in 1541 patients with systolic HF and mild to moderate anemia, enrolled in the Reduction of Events by darbepoetin alfa in Heart Failure (RED-HF) trial. Modifying effects and interaction with darbepoetin alfa treatment were also assessed.ResultsAll leukocyte markers, except granulysin, were associated with the primary outcome and all-cause death in univariate analysis (all p

Original languageEnglish
Pages (from-to)133-141
Number of pages9
JournalClinical Research in Cardiology
Volume108
Issue number2
DOIs
Publication statusPublished - Feb-2019

Keywords

  • Leukocyte
  • Monocyte
  • Macrophage
  • T cell
  • Heart failure
  • Prognosis
  • MIGRATION INHIBITORY FACTOR
  • DARBEPOETIN ALPHA
  • IRON-DEFICIENCY
  • MONOCYTE ACTIVATION
  • MYOCARDIAL INJURY
  • LEUKOCYTE
  • ERYTHROPOIETIN
  • INFLAMMATION
  • MACROPHAGE
  • MORTALITY

Cite this